Everest Medicines Limited (SEHK: 1952)
Health Care · Biotechnology · CN
HK$29.60
+3.35% today · -43.9% 1Y
Everest Medicines Limited (SEHK: 1952) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.33B and employs 812 people.
Over the last twelve months the share price has lost 43.9%, trading between 22.70 and 55.90.
Tweenvest scores Everest Medicines Limited across four factors: quality 46/100, value 81/100. Its strongest factor is value.
1952 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.33B
- Revenue (TTM)
- $354.55M
- P/E
- —
- EPS
- -0.17
- Dividend yield
- —
- Beta (5Y)
- 1.59
- 52-week high
- HK$55.90
- 52-week low
- HK$22.70
- Avg volume (3M)
- —
- Shares outstanding
- 351.58M
- Employees
- 812
- Next earnings
- —
About Everest Medicines Limited
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
- ISIN
- KYG3224E1061
- Founded
- 2017
- Listed since
- Oct 9, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Pharma Mar, S.A.BME: PHM | $1.35B | €68.30 | -1.66% |
| BeBetter Med Inc.SHSE: 688759 | $1.35B | CN¥20.05 | -7.56% |
| GNI Group Ltd.TSE: 2160 | $1.33B | ¥3,200.00 | -3.18% |
| Biotest GmbH & Co. KGaAHMSE: BIO0 | $1.33B | €30.00 | -9.64% |
| Ascentage Pharma Group InternationalSEHK: 6855 | $1.32B | HK$28.22 | -3.36% |
| Damora Therapeutics, Inc.NasdaqCM: DMRA | $1.30B | $20.22 | -4.08% |
| Liaoning Chengda Biotechnology Co., Ltd.SHSE: 688739 | $1.30B | CN¥21.20 | +0.86% |
| Vcanbio Cell & Gene Engineering Corp., LtdSHSE: 600645 | $1.30B | CN¥19.10 | +2.25% |
Figures last refreshed Oct 11, 2026.